昭栄薬品 has raised its consolidated earnings forecast for the second quarter of the fiscal year ending March 2027. Net sales have been raised to ¥15.836 billion, operating profit to ¥424 million, ordinary profit to ¥520 million and net profit attributable to owners of the parent to ¥351 million.
昭栄薬品 has raised its consolidated earnings forecast for the second quarter of the fiscal year ending March 2027. Net sales are now projected at ¥15.836 billion, up 17.0% from the previous forecast, while operating profit is projected at ¥424 million, up 103.3%; ordinary profit at ¥520 million, up 71.4%; and net profit attributable to owners of the parent at ¥351 million, up 71.7%.
The main factor was strong performance in the core chemicals business. Amid concerns over the outlook for the situation in the Middle East, customers moved to build up inventories, and order volumes from major domestic customers exceeded initial expectations. With prices for natural fats and oils remaining high, the increased pass-through of higher costs into selling prices also contributed to growth in sales and profit.
The full-year consolidated earnings forecast is currently under review and is scheduled to be announced when results for the second quarter are released on 11 November 2026.